Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 12Neoplasms 5Colorectal Neoplasms 5Neoplasm Metastasis 4Advanced Solid Tumors 3Pancreatic Neoplasms 2Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 2Venous Thromboembolism 1Thoracic Neoplasms 1Solid Tumor, Adult 1Solid Tumor 1Sexual Dysfunction, Physiological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Ovarian Neoplasms 1Noonan Syndrome 1Non-small Cell Lung Cancer Metastatic 1Non Small Lung Cancer 1Neoplasms by Site 1Mesothelioma 1Lung Diseases 1KRAS p.G12C Mutant Advanced Solid Tumors 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Hereditary Sensory and Autonomic Neuropathies 1Healthy Participants 1Fallopian Tube Neoplasms 1Eunuchism 1Erectile Dysfunction 1Endometrial Neoplasms 1

Interventions

Fulvestrant 10Alpelisib 7Everolimus 6Cetuximab 6Letrozole 4serabelisib 3ribociclib 3pembrolizumab 3palbociclib 3duvelisib 3berzosertib 3Paclitaxel 3PX-866 3NVP-BKM120 3Irinotecan 3sapanisertib 2parsaclisib 2olaparib 2binimetinib 2Topotecan 2Gemcitabine 2Carboplatin 2volagidemab 1venetoclax 1tivozanib 1tipifarnib 1tanezumab 1talazoparib 1sotorasib 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × sotorasib × Clear all
NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Revolution Medicines, Inc.

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡